NCT00380653 2021-12-13Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic SyndromesCyclacel Pharmaceuticals, Inc.Phase 1 Completed47 enrolled
NCT01211457 2019-07-16Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)Cyclacel Pharmaceuticals, Inc.Phase 1/2 Unknown65 enrolled